Targeting HSP47 may present a novel therapeutic approach to selectively modulate thrombus stability and size, potentially preventing excessive aggregation during acute conditions like myocardial infarction while still allowing necessary platelet–collagen adhesion for hemostasis. The gene discussed is SERPINH1; the disease is myocardial infarction.